Market Size of Short-acting Insulin Industry
| Study Period | 2019 - 2029 |
| Market Size (2024) | USD 7.23 Billion |
| Market Size (2029) | USD 8.58 Billion |
| CAGR (2024 - 2029) | 3.46 % |
| Fastest Growing Market | Middle-East and Africa |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Need a report that reflects how COVID-19 has impacted this market and its growth?
Short-acting Insulin Market Analysis
The Short-acting Insulin Market size is estimated at USD 7.23 billion in 2024, and is expected to reach USD 8.58 billion by 2029, growing at a CAGR of 3.46% during the forecast period (2024-2029).
There is not enough data saying that diabetes people are more likely to get COVID-19 than other healthy people, individuals with any kind of diabetes might differ in age, the number of complications they have had, and their level of diabetes management. Whatever kind of diabetes a person has, those who currently have diabetes-related health issues are more likely to experience poorer results if they get COVID-19. Leading suppliers of insulin drugs claim that at the moment, COVID-19 is not affecting their present capacity for producing and distributing products like insulin.
When a person has type 1 diabetes, their pancreas stops producing insulin. They require insulin injections to utilize the glucose from meals since their beta cells have been damaged.
Insulin is produced by people with type 2 diabetes, but their bodies do not respond effectively to it. Some patients with type 2 diabetes require insulin injections or diabetic medications to help their bodies utilize glucose as fuel. Insulin would be broken down during digestion, much like the protein in food, insulin cannot be given orally, to enter the bloodstream, it must be injected into the fat beneath the skin.
Currently, there are five main types of insulins (regular insulin, NPH, short-acting analogs, basal analogs, and pre-mixed insulin) being sold globally. Generally, insulin analogs are priced much higher than regular insulin or NPH, as they are bioengineered with altered amino-acid sequences to provide the desired chemical properties. In recent days, usage of short-acting analogs has been increasing due to the increasing Type 1 diabetes population.
Thus, owing to the above factors it is expected to drive the market growth over the forecast period.
Short-acting Insulin Industry Segmentation
Regular insulin is short-acting human-made insulin. It helps adults and children with Type 1 and Type 2 diabetes control their blood sugar levels. Take regular insulin 30 minutes before eating a meal. Short-Acting Insulin Market is segmented by Drug (Apidra (Glulisine), Novolog/Novorapid, Humalog (Lispro), Novolin (Actrapid), Insuman, Humulin, FIASP, and Admelog) and Geography (North America, Europe, Latin America, Asia Pacific, and Middle-East and Africa).
| Drug | ||||||||||
|
| Geography | |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
| |||||||||||||
|
Short-acting Insulin Market Size Summary
The Short-acting Insulin Market is poised for steady growth over the forecast period, driven by the increasing prevalence of diabetes globally. This market is characterized by the necessity of insulin injections for individuals with Type 1 diabetes, as their bodies do not produce insulin, and for some with Type 2 diabetes who cannot effectively utilize the insulin produced. The market features a range of insulin types, including regular insulin, NPH, short-acting analogs, basal analogs, and pre-mixed insulin, with short-acting analogs gaining traction due to their bioengineered properties and rising demand among Type 1 diabetes patients. The market's expansion is further supported by the growing awareness and adoption of insulin therapies, particularly in regions with high diabetes rates, such as the United States, where a significant portion of the population is affected by the condition.
The United States holds a dominant position in the Short-acting Insulin Market, accounting for a substantial share of the global revenue. This is largely attributed to the high diabetic population and the country's status as a key market for insulin drug manufacturers. The market is highly consolidated, with major players like Sanofi, Novo Nordisk, and Eli Lilly leading the charge. These companies are actively engaging in competitive strategies to enhance their market presence, including price reductions and initiatives to make insulin more accessible. Regulatory factors and government initiatives, such as the Medicare pilot program, aim to reduce insulin costs, potentially further stimulating market growth. The market's profitability also attracts generic insulin manufacturers, contributing to a dynamic and competitive landscape.
Short-acting Insulin Market Size - Table of Contents
-
1. MARKET INSIGHTS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.3 Market Restraints
-
1.4 Industry Attractiveness - Porter's Five Forces Analysis
-
1.4.1 Bargaining Power of Suppliers
-
1.4.2 Bargaining Power of Consumers
-
1.4.3 Threat of New Entrants
-
1.4.4 Threat of Substitute Products and Services
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION
-
2.1 Drug
-
2.1.1 Short-acting Insulins
-
2.1.1.1 Apidra (Glulisine)
-
2.1.1.2 Novolog/Novorapid
-
2.1.1.3 Humalog (Lispro)
-
2.1.1.4 Novolin (Actrapid)
-
2.1.1.5 Insuman
-
2.1.1.6 Humulin
-
2.1.1.7 FIASP
-
2.1.1.8 Admelog
-
-
-
2.2 Geography
-
2.2.1 North America
-
2.2.1.1 United States
-
2.2.1.2 Canada
-
2.2.1.3 Rest of North America
-
-
2.2.2 Europe
-
2.2.2.1 United Kingdom
-
2.2.2.2 Germany
-
2.2.2.3 France
-
2.2.2.4 Italy
-
2.2.2.5 Spain
-
2.2.2.6 Russia
-
2.2.2.7 Rest of Europe
-
-
2.2.3 Latin America
-
2.2.3.1 Mexico
-
2.2.3.2 Brazil
-
2.2.3.3 Rest of Latin America
-
-
2.2.4 Asia-Pacific
-
2.2.4.1 Japan
-
2.2.4.2 South Korea
-
2.2.4.3 China
-
2.2.4.4 India
-
2.2.4.5 Australia
-
2.2.4.6 Vietnam
-
2.2.4.7 Malaysia
-
2.2.4.8 Indonesia
-
2.2.4.9 The Philippines
-
2.2.4.10 Thailand
-
2.2.4.11 Rest of Asia-Pacific
-
-
2.2.5 Middle-East and Africa
-
2.2.5.1 Saudi Arabia
-
2.2.5.2 Iran
-
2.2.5.3 Egypt
-
2.2.5.4 Oman
-
2.2.5.5 South Africa
-
2.2.5.6 Rest of Middle-East and Africa
-
-
-
Short-acting Insulin Market Size FAQs
How big is the Short-acting Insulin Market?
The Short-acting Insulin Market size is expected to reach USD 7.23 billion in 2024 and grow at a CAGR of 3.46% to reach USD 8.58 billion by 2029.
What is the current Short-acting Insulin Market size?
In 2024, the Short-acting Insulin Market size is expected to reach USD 7.23 billion.
